Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06409663 · ClinicalTrials.gov registry record · Phase 3
A Strain Change Study for SARS-CoV-2 rS Vaccines
A Phase 3 study, sponsored by Novavax.
- Completed
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
NCT06409663 is a Phase 3 study that has completed, run by Novavax. The registered enrollment target is 60 participants.
The verdict
NCT06409663, a Phase 3 study, has completed, sponsored by Novavax.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
Study Summary
The present study aims to investigate the safety and immunogenicity of the Novavax JN.1 subvariant vaccine SARS-CoV-2 rS adjuvanted with Matrix-M (NVX CoV2705) in previously vaccinated adults. A descriptive comparison will be made with participants who received the prior authorized vaccine NVX-CoV2601 in an earlier study (2019nCoV-313).
Interventions
- BIOLOGICAL NVX-CoV2705 Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-10-14 |
| Est. Completion | 2025-04-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06409663
The ClinicalTrials.gov registry entry for NCT06409663 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novavax, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NVX-CoV2705 Vaccine is the first listed.
NCT06409663 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06409663 about?
NCT06409663 is a clinical study titled "A Strain Change Study for SARS-CoV-2 rS Vaccines". The present study aims to investigate the safety and immunogenicity of the Novavax JN.1 subvariant vaccine SARS-CoV-2 rS adjuvanted with Matrix-M (NVX CoV2705) in previously vaccinated adults. A descriptive comparison will be made with participants who received the prior authorized vaccine NVX-CoV26...
What is the current status of trial NCT06409663?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2024-10-14. Estimated completion is 2025-04-17.
What interventions are being tested in trial NCT06409663?
The interventions under investigation include: NVX-CoV2705 Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06409663?
This trial is sponsored by Novavax, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.